LOGIN  |  REGISTER
C4 Therapeutics
Viking Therapeutics

Publication Relating to a Transparency Notification

December 08, 2023 | Last Trade: US$7.80 0.52 -6.25

Mont-Saint-Guibert (Belgium), December 8, 2023, 10.30pm CET / 4.30pm ET – In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received a transparency notification as detailed below.

On December 6, 2023, Nyxoah received a transparency notification from Deerfield Partners, L.P. indicating that Deerfield Partners, L.P. crossed the 3% threshold on November 30, 2023, after which Deerfield Partners, L.P. holds 856,085 shares, representing 2.99% of the total number of voting rights on November 30, 2023 (28,673,985).

The notification dated December 6, 2023 contains the following information:

  • Reason for the notification:
    • Acquisition or disposal of voting securities or voting rights
    • Downward crossing of the lowest threshold
  • Notification by: a parent undertaking or a controlling person
  • Persons subject to the notification requirement:
    • James E. Flynn
    • Deerfield Partners, L.P. (with address at 345 Park Ave S., 12th FL, New York, NY 10010 United States)
    • Deerfield Mgmt, L.P. (with address at 345 Park Ave S., 12th FL, New York, NY 10010 United States)
    • J.E. Flynn Capital, LLC (with address at 345 Park Ave S., 12th FL, New York, NY 10010 United States)
    • Deerfield Management Company, L.P. (with address at 345 Park Ave S., 12th FL, New York, NY 10010 United States)
    • Flynn Management LLC (with address at 345 Park Ave S., 12th FL, New York, NY 10010 United States)
  • Date on which the threshold was crossed: November 30, 2023
  • Threshold that is crossed: 3%
  • Denominator: 28,673,985
  • Notified details:
A) Voting rightsPrevious notificationAfter the transaction
 # of voting rights# of voting rights% of voting rights
Holders of voting rights Linked to securitiesNot linked to the
securities
Linked to securitiesNot linked to the
securities
James E. Flynn0000.00%0.00%
Deerfield Partners, L.P.899,300856,08502.99%0.00%
Subtotal899,300856,085 2.99% 
 TOTAL856,08502.99%0.00%
  • Chain of controlled undertakings through which the holding is effectively held: Deerfield Partners, L.P. is controlled by (i) Deerfield Mgmt L.P., which is controlled by J.E. Flynn Capital, LLC and (ii) Deerfield Management Company, L.P., which is controlled by Flynn Management LLC. Both Flynn Management LLC and J.E. Flynn Capital, LLC are controlled by James E. Flynn.
  • Additional information: a sale of shares by Deerfield Partners, L.P.

Contact:
Nyxoah
David DeMartino, Chief Strategy Officer
This email address is being protected from spambots. You need JavaScript enabled to view it.
+1 310 310 1313

Chimerix

Stock Quote

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

Featured Stock

Amneal Pharmaceuticals

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page